Drug intelligence / Profile preview

MicroLock Patch

Development stage: Preclinical
Lead developer: CuRsuS Bio
Modality: Peptides
Administration: Transdermal

Overview

MicroLock Patch is a transdermal drug delivery system developed by CuRsuS Bio, utilizing their proprietary MicroLock® microneedle technology to deliver a Glucagon-like peptide 1 (GLP-1) receptor agonist. Designed for the treatment of obesity, the patch features a unique microneedle structure that ensures secure skin adhesion and efficient penetration of the stratum corneum. This modality offers a minimally invasive, self-administrable alternative to traditional subcutaneous injections, potentially improving patient compliance and providing a sustained release profile of the therapeutic peptide. The program is currently in the preclinical stage of development.

Brand names: MicroLock Patch
Other names: MicroLock® PatchCuRsuS Bio GLP-1 receptor-transdermal microneedle patch

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on MicroLock Patch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroLock Patch.

Explore the full profile